NCT00430261View on ClinicalTrials.gov

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Lung CancerAdenocarcinoma

Interventions

DRUG

sunitinib

50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.

Trial Locations (1)

98104

Swedish Cancer Institute, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Swedish Medical Center

OTHER